# OnCo record ottimo-pharma (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/ottimo-pharma/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "ottimo-pharma" ;
  schema:name "Ottimo Pharma"@en ;
  schema:description "Ottimo Pharma is testing a single antibody that both releases an immune brake (PD-1) and blocks a growth signal tumours use to build blood vessels (VEGFR2). It began its first human trial in the United States and Australia in early 2026."@en ;
  schema:url <https://onco.cc/companies/ottimo-pharma/>, <https://ottimopharma.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://ottimopharma.com/>, <https://ottimopharma.com/ottimo-pharma-emerges-from-stealth-with-backing-from-medicxi-and-management-team-led-by-david-epstein-to-accelerate-development-of-a-novel-pd1-vegfr2-bi-functional-antibody-planned-to-enter-the-clinic/>, <https://ottimopharma.com/ottimo-pharma-raises-over-140-million-in-series-a-financing/>, <https://ottimopharma.com/fda-nda-clearance-otp-01/> ;
  schema:addressCountry "GB" ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/vegf/> ;
  onco:trials <https://onco.cc/trials/nct07266428/> .